Intravenous Administration of REOLYSIN® in Combination with Paclitaxel and Carboplatin for Patients with Advanced Head and Neck Cancers
In March 2011, Oncolytics announced that it had completed enrollment in a US Phase II clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.
This trial is a fourteen patient, single-arm, open-label, dose-targeted, non-randomized, multicenter trial of REOLYSIN® given intravenously in combination with a standard dosage of paclitaxel and carboplatin.
Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase II trial is to measure tumor responses and duration of response, and to describe any evidence of antitumor activity. The secondary objective is to determine the safety and tolerability of REOLYSIN® when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancer.
- November 14, 2011: Oncolytics Biotech® Inc. Announces Positive Results of U.S. Phase 2 Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers (Press Release)
March 24, 2011: Oncolytics Biotech Inc. Completes Patient Enrollment in US Phase II Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers (Press Release)